Dr Borghaei on Determining Treatments Utilizing Biomarker Testing in NSCLC

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Related Keywords

Edmundm Dunn ,Hossein Borghaei ,Department Of Hematology Oncology ,Division Of Thoracic Medical Oncology ,Fox Chase Cancer Center At Temple Health ,Thoracic Medical Oncology ,Immune Monitoring Facility ,Thoracic Oncology ,Fox Chase Cancer Center ,Temple Health ,Per New York Lung Cancer Symposium ,News ,Lung Cancer ,